US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
Mike Dolph, 1 Gabriel Tremblay, 1 Hoyee Leong 2 1Health Economics Department, Purple Squirrel Economics, New York, NY, 10010, USA; 2Health Economics and Outcomes Research, Global Medical and Scientific Affairs, Karyopharm Therapeutics, Newton, MA, 02459, USACorrespondence: Hoyee Leong Email hleong@k...
Saved in:
Main Authors: | Dolph M (Author), Tremblay G (Author), Leong H (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
by: Bassali J, et al.
Published: (2020) -
Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
by: Amany R Keruakous, et al.
Published: (2021) -
Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
by: Paweł Robak, et al.
Published: (2020) -
Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020) -
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
by: Joseph NS, et al.
Published: (2021)